Donna Wilcock, PhD, of the UK’s Sanders-Brown Center on Aging (SBCoA) was awarded a $1.7 million National Institutes of Health grant for her lab’s exploration of adverse effects of two new Alzheimer’s disease drugs. “The goal ultimately is to show data that will hopefully support a potential adjunct therapy that could be used with these antibodies, that would make them safer for more of the population,” said Wilcock.
Wilcock is joined on this grant by colleagues affiliated with UK’s Sanders-Brown Center on Aging: David Fardo, PhD, and Yuriko Katsumata, PhD, both from the College of Public Health; and Joseph Morganti, PhD, from the College of Medicine.
There currently is no cure for Alzheimer’s disease. Wilcock says drugs like aducanumab and lecanemab that slow disease progression are critically important as they help to provide some hope for those living with dementia and their families.
This article appears on page 14 of the December 2022 issue of Hamburg Journal. To subscribe, click here.
